Actinium Pharmaceuticals ... (ATNM)
1.91
0.04 (2.14%)
At close: Mar 27, 2025, 3:59 PM
1.91
0.26%
After-hours: Mar 27, 2025, 07:29 PM EDT
Actinium Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 | FY06 |
| Revenue | 81K | 1.03M | 1.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 699K | 524K | 447K | 420.09K | 50.72K | 55.94K | 77.52K | 53.47K | n/a | 4.12K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | 81K | 331K | 620K | -447K | -420.09K | -50.72K | -55.94K | -77.52K | -53.47K | n/a | -4.12K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Income | -51.92M | -34.1M | -24.96M | -22.39M | -22.07M | -23.83M | -26.91M | -26.85M | -24.83M | -22.48M | -6.59M | -7.95M | -9.95K | -26.05K | -16.02K | -26.42K | -11.99K | -17.53K |
| Interest Income | 3.1M | 1.09M | 190K | 178K | 172.39K | 173.36K | 5.43K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -48.82M | -33.02M | -24.77M | -22.21M | -21.9M | -23.65M | -26.6M | -24.32M | -21.03M | -24.69M | -10.77M | -8.36M | 10.29K | 1.67K | -22.33K | n/a | n/a | n/a |
| Net Income | -48.82M | -31.93M | -24.58M | -22.04M | -21.73M | -23.65M | -26.6M | -24.32M | -21.03M | -24.69M | -10.77M | -8.36M | 10.29K | 1.67K | -22.33K | -31.24K | -14.8K | -18.4K |
| Selling & General & Admin | 13.33M | 12M | 8.08M | 6.31M | 5.52M | 6.73M | 9.16M | 9.27M | 11.46M | 10.18M | 3.92M | 4.51M | 9.62K | 25.41K | 14.54K | 18.92K | 11.01K | 17.53K |
| Research & Development | 38.67M | 23.14M | 18.03M | 16.09M | 16.55M | 17.09M | 17.7M | 17.5M | 13.31M | 12.27M | 2.67M | 3.44M | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 55.94K | 77.52K | 53.47K | 37.91K | 1.56K | 581.00 | n/a | n/a | n/a | n/a | 982.00 | n/a |
| Operating Expenses | 52M | 35.13M | 26.11M | 22.39M | 22.07M | 23.83M | 26.91M | 26.85M | 24.83M | 22.48M | 6.59M | 7.95M | 9.62K | 25.41K | 14.54K | 26.42K | 11.99K | 17.53K |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | 173.36K | 5.43K | 5.01K | 7.87K | 866.00 | 2.51K | 1.1M | 4.76K | 6.62K | 6.4K | 4.82K | 2.81K | 870.00 |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 52M | 35.13M | 26.11M | 22.39M | 22.07M | 23.83M | 26.91M | 26.85M | 24.83M | 22.48M | 6.59M | 7.95M | 9.62K | 25.41K | 14.54K | 26.42K | 11.99K | 17.53K |
| Income Tax | n/a | -1.09M | -190K | -178K | -172.39K | 173.36K | -309.55K | 5.01K | 7.87K | 866.00 | 2.51K | 1.1M | 4.42K | 5.97K | 4.91K | 31.24K | 14.8K | 18.4K |
| Shares Outstanding (Basic) | 26.6M | 24.14M | 20.57M | 12.13M | 4.98M | 3.53M | 2.22M | 1.62M | 1.27M | 912.12K | 758.42K | 36.78K | 26.73K | 371.83K | 371.83K | 371.83K | 371.83K | 76.99K |
| Shares Outstanding (Diluted) | 26.6M | 24.14M | 20.57M | 12.13M | 4.98M | 3.53M | 2.22M | 1.62M | 1.27M | 912.12K | 758.42K | 36.78K | 26.73K | 371.83K | 371.83K | 371.83K | 371.83K | 76.99K |
| EPS (Basic) | -1.83 | -1.32 | -1.2 | -1.82 | -4.37 | -6.69 | -11.96 | -15.06 | -16.53 | -27.07 | -14.21 | -227.31 | 0.38 | 0.00 | -0.06 | -0.08 | -0.04 | -0.24 |
| EPS (Diluted) | -1.83 | -1.32 | -1.2 | -1.82 | -4.37 | -6.69 | -11.96 | -15.06 | -16.53 | -27.07 | -14.21 | -227.31 | 0.38 | 0.00 | -0.06 | -0.08 | -0.04 | -0.24 |
| EBITDA | -51.13M | -33.41M | -24.44M | -21.77M | -21.48M | -23.78M | -26.85M | -26.77M | -24.78M | -22.44M | -6.59M | -7.95M | 15.05K | 8.29K | -14.54K | -26.32K | -11.99K | -17.53K |
| Depreciation & Amortization | 790K | 699K | 524K | 447K | 420.09K | 50.72K | 55.94K | 77.52K | 53.47K | 37.91K | 1.56K | 581.00 | 337.00 | 648.00 | 1.49K | n/a | n/a | n/a |